8-K Announcements
6Material company update
Mar 23, 2026·SEC
Material company update
Mar 20, 2026·SEC
Material company update
Feb 20, 2026·SEC
Exact Sciences Corporation(EXAS)Earnings, Financials & Key Ratios
EXAS•NASDAQ
$104.91
$20.02B mkt cap·Price updated Apr 24, 2026
AboutExact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.Show more
- Revenue$3.25B+17.7%
- EBITDA-$206M+75.3%
- Net Income-$208M+79.8%
- EPS (Diluted)-1.10+80.3%
- Gross Margin69.69%+0.2%
- EBITDA Margin-6.35%+79.0%
- Operating Margin-6.35%+83.3%
- Net Margin-6.4%+82.8%
- ROE-8.66%+76.7%
- ROIC-3.63%+77.7%
- Debt/Equity1.05-8.4%
EXAS Key Insights
Exact Sciences Corporation (EXAS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong Piotroski F-Score: 7/9
- ✓Momentum leader: RS Rating 91 (top 9%)
- ✓Strong 5Y sales CAGR of 16.8%
- ✓Trading near 52-week high
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
EXAS Price & Volume
Exact Sciences Corporation (EXAS) stock price & volume — 10-year historical chart
Loading chart...
EXAS Growth Metrics
Exact Sciences Corporation (EXAS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years55.44%
5 Years16.84%
3 Years15.92%
TTM17.69%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM79.79%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM80.3%
Return on Capital
10 Years-17.61%
5 Years-10.54%
3 Years-8.81%
Last Year-3.96%
EXAS Recent Earnings
Exact Sciences Corporation (EXAS) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 11/12 qtrs (92%)
Q1 2026Latest
Feb 13, 2026EPS
$0.45
Est $0.11
-316.9%
Revenue
$878M
Est $861M
+2.0%
Q4 2025
Nov 3, 2025EPS
$0.24
Est $0.06
+492.0%
Revenue
$851M
Est $811M
+5.0%
Q3 2025
Aug 6, 2025EPS
$0.22
Est $0.02
+1200.0%
Revenue
$811M
Est $810M
+0.1%
Q2 2025
May 1, 2025EPS
$0.21
Est $0.37
+43.2%
Revenue
$707M
Est $689M
+2.6%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 13, 2026 | $0.45vs $0.11-316.9% | $878Mvs $861M+2.0% |
| Q4 2025 | Nov 3, 2025 | $0.24vs $0.06+492.0% | $851Mvs $811M+5.0% |
| Q3 2025 | Aug 6, 2025 | $0.22vs $0.02+1200.0% | $811Mvs $810M+0.1% |
| Q2 2025 | May 1, 2025 | $0.21vs $0.37+43.2% | $707Mvs $689M+2.6% |
Based on last 12 quarters of dataView full earnings history →
EXAS Peer Comparison
Exact Sciences Corporation (EXAS) competitors in Molecular and Genetic Diagnostics — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 GH | 11.53B | 92.25 | -27.79 | 32.88% | -44.18% | |||
 NTRA | 29.58B | 215.09 | -140.58 | 56.75% | -14.61% | -24.69% | 0.16 | |
 ILMN | 21.66B | 142.58 | 26.16 | -0.78% | 19.43% | 32.84% | 0.94 | |
 LH | 21.14B | 256.93 | 24.56 | 7.25% | 6.66% | 10.89% | 0.83 | |
 DGX | 20.93B | 189.13 | 21.61 | 11.78% | 9.08% | 13.8% | 0.95 | |
 NEOG | 2B | 9.18 | -1.83 | -3.2% | -68.47% | -28.64% | 0.44 | |
 CDNA | 1.08B | 20.94 | -52.35 | 13.79% | -1.98% | -2.61% | 0.06 | |
 TMO | 175.76B | 472.95 | 26.66 | 3.91% | 15.18% | 13.23% | 0.76 |
Compare EXAS vs Peers
Exact Sciences Corporation (EXAS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
EXAS Income Statement
Exact Sciences Corporation (EXAS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 265.99M | 454.46M | 876.29M | 1.49B | 1.77B | 2.08B | 2.5B | 2.76B | 3.25B |
| Revenue Growth % | 167.66% | 70.86% | 92.82% | 70.19% | 18.49% | 17.95% | 19.93% | 10.37% | 17.69% |
| Cost of Goods Sold | 79.2M | 117.98M | 216.72M | 354.3M | 458.76M | 661.36M | 737.6M | 840.2M | 984.24M |
| COGS % of Revenue | 29.77% | 25.96% | 24.73% | 23.76% | 25.96% | 31.73% | 29.51% | 30.45% | 30.31% |
| Gross Profit | 186.79M▲ 0% | 336.48M▲ 80.1% | 659.58M▲ 96.0% | 1.14B▲ 72.4% | 1.31B▲ 15.1% | 1.42B▲ 8.8% | 1.76B▲ 23.8% | 1.92B▲ 8.9% | 2.26B▲ 17.9% |
| Gross Margin % | 70.23% | 74.04% | 75.27% | 76.24% | 74.04% | 68.27% | 70.49% | 69.55% | 69.69% |
| Gross Profit Growth % | 244.76% | 80.14% | 96.02% | 72.4% | 15.06% | 8.76% | 23.84% | 8.88% | 17.93% |
| Operating Expenses | 305.1M | 495.95M | 893.36M | 1.9B | 2.16B | 2.02B | 1.98B | 2.97B | 2.46B |
| OpEx % of Revenue | 114.71% | 109.13% | 101.95% | 127.72% | 122.46% | 96.74% | 79.09% | 107.56% | 75.82% |
| Selling, General & Admin | 262.96M | 427.74M | 737.63M | 1.07B | 1.66B | 1.59B | 1.62B | 1.67B | 1.94B |
| SG&A % of Revenue | 98.86% | 94.12% | 84.18% | 71.83% | 94.12% | 76.43% | 64.82% | 60.46% | 59.71% |
| Research & Development | 42.14M | 68.21M | 139.69M | 554.05M | 385.65M | 394.19M | 426.93M | 431.21M | 523M |
| R&D % of Revenue | 15.84% | 15.01% | 15.94% | 37.15% | 21.82% | 18.91% | 17.08% | 15.63% | 16.11% |
| Other Operating Expenses | 0 | 0 | 16.04M | 279.42M | 115.21M | 29.21M | -70.05M | 868.06M | 0 |
| Operating Income | -118.31M▲ 0% | -159.47M▼ 34.8% | -233.78M▼ 46.6% | -767.7M▼ 228.4% | -855.68M▼ 11.5% | -593.51M▲ 30.6% | -215.01M▲ 63.8% | -1.05B▼ 387.7% | -206.3M▲ 80.3% |
| Operating Margin % | -44.48% | -35.09% | -26.68% | -51.48% | -48.42% | -28.48% | -8.6% | -38.01% | -6.35% |
| Operating Income Growth % | 30% | -34.79% | -46.6% | -228.38% | -11.46% | 30.64% | 63.77% | -387.74% | 80.33% |
| EBITDA | -102.75M | -136.39M | -183.53M | -604.33M | -675.33M | -395.95M | -8.4M | -833.84M | -206.3M |
| EBITDA Margin % | -38.63% | -30.01% | -20.94% | -40.52% | -38.22% | -19% | -0.34% | -30.22% | -6.35% |
| EBITDA Growth % | 34.76% | -32.73% | -34.57% | -229.27% | -11.75% | 41.37% | 97.88% | -9821.99% | 75.26% |
| D&A (Non-Cash Add-back) | 15.55M | 23.08M | 50.25M | 163.36M | 180.35M | 197.56M | 206.61M | 214.86M | 0 |
| EBIT | -114.38M | -140.54M | -397.71M | -817.24M | -829.63M | -618.66M | -177.32M | -1B | 0 |
| Net Interest Income | -206K | -36.79M | -27.27M | -10.55M | -12.88M | -13.91M | -24.42M | -31.97M | 0 |
| Interest Income | 0 | 0 | 23.77M | 6.57M | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 206K | 36.79M | 51.04M | 17.12M | 12.88M | 13.91M | 24.42M | 31.97M | -39.36M |
| Other Income/Expense | 3.73M | -15.59M | -172.66M | -61.37M | 13.17M | -39.06M | 13.27M | 12.54M | -5.71M |
| Pretax Income | -114.58M▲ 0% | -175.06M▼ 52.8% | -406.44M▼ 132.2% | -829.06M▼ 104.0% | -842.51M▼ 1.6% | -632.57M▲ 24.9% | -201.75M▲ 68.1% | -1.04B▼ 413.6% | -212.01M▲ 79.5% |
| Pretax Margin % | -43.08% | -38.52% | -46.38% | -55.59% | -47.68% | -30.35% | -8.07% | -37.56% | -6.53% |
| Income Tax | -187K | 92K | -193.35M | -5.46M | -246.88M | -9.06M | 2.4M | -7.3M | -4.06M |
| Effective Tax Rate % | 0.16% | -0.05% | 47.57% | 0.66% | 29.3% | 1.43% | -1.19% | 0.7% | 1.92% |
| Net Income | -114.4M▲ 0% | -175.15M▼ 53.1% | -213.09M▼ 21.7% | -823.61M▼ 286.5% | -595.63M▲ 27.7% | -623.51M▼ 4.7% | -204.15M▲ 67.3% | -1.03B▼ 404.0% | -207.95M▲ 79.8% |
| Net Margin % | -43.01% | -38.54% | -24.32% | -55.22% | -33.71% | -29.91% | -8.17% | -37.29% | -6.4% |
| Net Income Growth % | 31.59% | -53.11% | -21.66% | -286.51% | 27.68% | -4.68% | 67.26% | -403.97% | 79.79% |
| Net Income (Continuing) | -114.4M | -175.15M | -213.09M | -823.61M | -595.63M | -623.51M | -204.15M | -1.03B | 0 |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.99▲ 0% | -1.43▼ 44.4% | -1.62▼ 13.3% | -5.45▼ 236.4% | -3.48▲ 36.1% | -3.54▼ 1.7% | -1.13▲ 68.1% | -5.59▼ 394.7% | -1.10▲ 80.3% |
| EPS Growth % | 39.26% | -44.44% | -13.29% | -236.42% | 36.15% | -1.72% | 68.08% | -394.69% | 80.32% |
| EPS (Basic) | -0.99 | -1.43 | -1.62 | -5.45 | -3.48 | -3.54 | -1.13 | -5.59 | -1.10 |
| Diluted Shares Outstanding | 115.68M | 122.21M | 131.26M | 151.14M | 171.35M | 176.35M | 180.14M | 184.2M | 188.69M |
| Basic Shares Outstanding | 115.68M | 122.21M | 131.26M | 151.14M | 171.35M | 176.35M | 180.14M | 184.2M | 188.69M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
EXAS Balance Sheet
Exact Sciences Corporation (EXAS) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 487.22M | 1.23B | 553.94M | 2.2B | 1.43B | 982.26M | 1.19B | 1.57B | 1.56B |
| Cash & Short-Term Investments | 424.71M | 1.12B | 323.65M | 1.84B | 1.03B | 632.06M | 777.64M | 1.04B | 964.71M |
| Cash Only | 77.49M | 160.43M | 177.25M | 1.49B | 315.47M | 242.49M | 605.38M | 600.89M | 956M |
| Short-Term Investments | 347.22M | 963.75M | 146.4M | 348.7M | 715M | 389.56M | 172.27M | 437.14M | 8.71M |
| Accounts Receivable | 26.42M | 45.33M | 130.36M | 233.19M | 216.65M | 158.04M | 203.62M | 248.97M | 298.65M |
| Days Sales Outstanding | 36.25 | 36.41 | 54.3 | 57.07 | 44.75 | 27.68 | 29.73 | 32.94 | 33.57 |
| Inventory | 26.03M | 39.15M | 61.72M | 92.27M | 104.99M | 118.26M | 127.47M | 162.38M | 166.2M |
| Days Inventory Outstanding | 119.95 | 121.11 | 103.96 | 95.05 | 83.54 | 65.27 | 63.08 | 70.54 | 61.63 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 73.9M | 85.63M | 122.05M | 126.28M |
| Total Non-Current Assets | 111.34M | 295.95M | 2.95B | 2.73B | 5.26B | 5.24B | 5.28B | 4.36B | 4.3B |
| Property, Plant & Equipment | 79.99M | 245.26M | 581.77M | 577.93M | 754.47M | 851.76M | 842.06M | 810.63M | 831M |
| Fixed Asset Turnover | 3.33x | 1.85x | 1.51x | 2.58x | 2.34x | 2.45x | 2.97x | 3.40x | 3.91x |
| Goodwill | 1.98M | 17.28M | 1.2B | 1.24B | 2.34B | 2.35B | 2.37B | 2.37B | 2.37B |
| Intangible Assets | 22.23M | 29M | 1.14B | 847.12M | 2.09B | 1.96B | 1.89B | 1.01B | 919.92M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 7.15M | 4.42M | 23.32M | 63.77M | 74.59M | 90.58M | 177.39M | 169.72M | 185.81M |
| Total Assets | 598.56M▲ 0% | 1.52B▲ 154.6% | 3.51B▲ 130.0% | 4.93B▲ 40.5% | 6.68B▲ 35.7% | 6.23B▼ 6.9% | 6.47B▲ 3.9% | 5.93B▼ 8.4% | 5.86B▼ 1.1% |
| Asset Turnover | 0.44x | 0.30x | 0.25x | 0.30x | 0.26x | 0.33x | 0.39x | 0.47x | 0.55x |
| Asset Growth % | 58.75% | 154.61% | 130.03% | 40.49% | 35.73% | -6.85% | 3.93% | -8.39% | -1.14% |
| Total Current Liabilities | 68.12M | 136.59M | 236.49M | 633.1M | 517.07M | 412.75M | 514.7M | 732.19M | 641.15M |
| Accounts Payable | 16.14M | 28.14M | 25.97M | 35.71M | 67.83M | 74.92M | 78.82M | 89.57M | 175.87M |
| Days Payables Outstanding | 74.36 | 87.06 | 43.74 | 36.79 | 53.97 | 41.35 | 39 | 38.91 | 65.22 |
| Short-Term Debt | 182K | 8K | 834K | 314.03M | 0 | 0 | 50M | 249.15M | 33.59M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 29.08M | 44.51M | 103.63M | 162.92M | 214.49M | 211.5M | 262.44M | 223.7M | 607.56M |
| Current Ratio | 7.15x | 8.99x | 2.34x | 3.47x | 2.76x | 2.38x | 2.32x | 2.15x | 2.43x |
| Quick Ratio | 6.77x | 8.70x | 2.08x | 3.33x | 2.56x | 2.09x | 2.07x | 1.92x | 2.17x |
| Cash Conversion Cycle | 81.84 | 70.46 | 114.51 | 115.33 | 74.32 | 51.6 | 53.81 | 64.57 | 29.99 |
| Total Non-Current Liabilities | 10.02M | 706.91M | 981.21M | 2.06B | 2.78B | 2.77B | 2.81B | 2.79B | 2.82B |
| Long-Term Debt | 4.27M | 689.24M | 827.64M | 1.88B | 2.18B | 2.24B | 2.31B | 2.32B | 2.49B |
| Capital Lease Obligations | 0 | 0 | 118.67M | 121.08M | 182.17M | 182.4M | 161.07M | 157.13M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 5.75M | 17.67M | 34.91M | 51.34M | 417.78M | 352.46M | 335.98M | 315.5M | 329.32M |
| Total Liabilities | 78.14M | 843.08M | 1.22B | 2.69B | 3.3B | 3.18B | 3.33B | 3.53B | 3.46B |
| Total Debt | 4.45M | 689.25M | 955.03M | 2.33B | 2.38B | 2.45B | 2.55B | 2.75B | 2.52B |
| Net Debt | -73.04M | 528.82M | 777.77M | 839.33M | 2.07B | 2.2B | 1.95B | 2.15B | 1.57B |
| Debt / Equity | 0.01x | 1.01x | 0.42x | 1.04x | 0.70x | 0.80x | 0.81x | 1.15x | 1.05x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -574.32x | -4.33x | -4.58x | -44.84x | -66.44x | -42.68x | -8.80x | -32.80x | - |
| Total Equity | 520.42M▲ 0% | 680.94M▲ 30.8% | 2.29B▲ 236.0% | 2.24B▼ 2.3% | 3.39B▲ 51.5% | 3.04B▼ 10.2% | 3.15B▲ 3.4% | 2.4B▼ 23.6% | 2.4B▼ 0.0% |
| Equity Growth % | 55.21% | 30.84% | 236.01% | -2.29% | 51.53% | -10.17% | 3.36% | -23.62% | -0.05% |
| Book Value per Share | 4.50 | 5.57 | 17.43 | 14.79 | 19.77 | 17.26 | 17.46 | 13.04 | 12.72 |
| Total Shareholders' Equity | 520.42M | 680.94M | 2.29B | 2.24B | 3.39B | 3.04B | 3.15B | 2.4B | 2.4B |
| Common Stock | 1.21M | 1.23M | 1.48M | 1.59M | 1.74M | 1.78M | 1.81M | 1.86M | 1.91M |
| Retained Earnings | -860.61M | -1.04B | -1.12B | -2.05B | -2.64B | -3.27B | -3.47B | -4.5B | -4.71B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -750K | -1.42M | -100K | 526K | -1.44M | -5.24M | 1.43M | -944K | 2.36M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EXAS Cash Flow Statement
Exact Sciences Corporation (EXAS) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -71.72M | -69.33M | -111.66M | 136.48M | -102.24M | -223.56M | 156.12M | 210.54M | 491.44M |
| Operating CF Margin % | -26.96% | -15.25% | -12.74% | 9.15% | -5.79% | -10.73% | 6.25% | 7.63% | 15.14% |
| Operating CF Growth % | 44.86% | 3.34% | -61.06% | 222.24% | -174.91% | -118.67% | 169.83% | 34.86% | 133.42% |
| Net Income | -114.4M | -175.15M | -213.09M | -848.53M | -595.63M | -623.51M | -204.15M | -1.03B | -207.95M |
| Depreciation & Amortization | 15.55M | 23.08M | 50.25M | 163.36M | 180.35M | 197.56M | 206.61M | 214.86M | 221.58M |
| Stock-Based Compensation | 35.51M | 60.26M | 108.48M | 152.91M | 253.06M | 206.82M | 231.31M | 214.88M | 217.67M |
| Deferred Taxes | -115K | -2.78M | -193.6M | -9.86M | -253.17M | -11.9M | -955K | -10.12M | -1.54M |
| Other Non-Cash Items | -601K | 26.17M | 189.87M | 721.34M | 202.04M | 33.84M | -76.36M | 875.78M | 261.69M |
| Working Capital Changes | -7.68M | -911K | -53.56M | -42.73M | 111.11M | -26.38M | -342K | -56.01M | 0 |
| Change in Receivables | -17.53M | -17.29M | -27.63M | -100.53M | 25.15M | 61.09M | -43.42M | -46.26M | -48.89M |
| Change in Inventory | -19.19M | -12.73M | -19.04M | -30.31M | -9.22M | -13.23M | -7.69M | -34.91M | -3.77M |
| Change in Payables | 15.38M | 11.33M | 0 | 46.38M | 0 | 0 | 0 | 43.54M | 214.04M |
| Cash from Investing | -160.81M | -781.91M | -124.43M | -702.04M | -1.08B | 74.07M | 49.68M | -442.15M | 195.12M |
| Capital Expenditures | -69.24M | -150.67M | -172.65M | -64.35M | -135.77M | -214.46M | -124.19M | -135.99M | -134.66M |
| CapEx % of Revenue | 26.03% | 33.15% | 19.7% | 4.31% | 7.68% | 10.29% | 4.97% | 4.93% | 4.15% |
| Acquisitions | -5.98M | -17.91M | -973.86M | -22.61M | -517.77M | -14.69M | -52.41M | -45M | -75M |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | -109.34M | -614.3M | -1M | -411.8M | -58.82M | 24.45M | -250K | -225K | 28.27M |
| Cash from Financing | 260.96M | 934.14M | 253.18M | 1.88B | 8.47M | 76.48M | 159.77M | 231.87M | -338.09M |
| Debt Issued (Net) | -376K | 920.67M | 236.12M | 974.24M | -23.75M | 50M | 137.98M | 216.75M | 0 |
| Equity Issued (Net) | 1000K | 0 | 0 | 1000K | 0 | 0 | 0 | 1000K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 4.89M | 0 | 0 | 0 | 0 | 0 | 0 | 26.54M |
| Other Financing | 7.94M | 13.48M | 17.06M | 43.68M | 32.22M | 26.48M | 21.79M | -17.75M | -338.09M |
| Net Change in Cash | 28.57M▲ 0% | 82.94M▲ 190.3% | 17.1M▼ 79.4% | 1.31B▲ 7585.5% | -1.18B▼ 189.5% | -72.98M▲ 93.8% | 366.88M▲ 602.7% | -3.04M▼ 100.8% | 349.36M▲ 11595.9% |
| Free Cash Flow | -140.96M▲ 0% | -220M▼ 56.1% | -284.31M▼ 29.2% | 72.13M▲ 125.4% | -238M▼ 430.0% | -438.02M▼ 84.0% | 31.93M▲ 107.3% | 74.55M▲ 133.5% | 356.78M▲ 378.6% |
| FCF Margin % | -53% | -48.41% | -32.44% | 4.84% | -13.47% | -21.02% | 1.28% | 2.7% | 10.99% |
| FCF Growth % | 2.73% | -56.07% | -29.23% | 125.37% | -429.96% | -84.04% | 107.29% | 133.48% | 378.6% |
| FCF per Share | -1.22 | -1.80 | -2.17 | 0.48 | -1.39 | -2.48 | 0.18 | 0.40 | 1.89 |
| FCF Conversion (FCF/Net Income) | 0.63x | 0.40x | 0.52x | -0.17x | 0.17x | 0.36x | -0.76x | -0.20x | -2.36x |
| Interest Paid | 0 | 0 | 5.13M | 0 | 10.73M | 11.52M | 18.78M | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EXAS Key Ratios
Exact Sciences Corporation (EXAS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -50.51% | -26.74% | -29.16% | -14.35% | -36.41% | -21.18% | -19.39% | -6.6% | -37.09% | -8.66% |
| Return on Invested Capital (ROIC) | -43.44% | -24.01% | -14.43% | -8.2% | -18.75% | -15.05% | -8.32% | -3.12% | -16.3% | -3.63% |
| Gross Margin | 54.52% | 70.23% | 74.04% | 75.27% | 76.24% | 74.04% | 68.27% | 70.49% | 69.55% | 69.69% |
| Net Margin | -168.26% | -43.01% | -38.54% | -24.32% | -55.22% | -33.71% | -29.91% | -8.17% | -37.29% | -6.4% |
| Debt / Equity | 0.02x | 0.01x | 1.01x | 0.42x | 1.04x | 0.70x | 0.80x | 0.81x | 1.15x | 1.05x |
| Interest Coverage | -793.50x | -574.32x | -4.33x | -4.58x | -44.84x | -66.44x | -42.68x | -8.80x | -32.80x | - |
| FCF Conversion | 0.78x | 0.63x | 0.40x | 0.52x | -0.17x | 0.17x | 0.36x | -0.76x | -0.20x | -2.36x |
| Revenue Growth | 151.99% | 167.66% | 70.86% | 92.82% | 70.19% | 18.49% | 17.95% | 19.93% | 10.37% | 17.69% |
EXAS SEC Filings & Documents
Exact Sciences Corporation (EXAS) SEC filings — annual & quarterly reports (10-K, 10-Q)
EXAS Frequently Asked Questions
Exact Sciences Corporation (EXAS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Exact Sciences Corporation (EXAS) reported $3.25B in revenue for fiscal year 2025.
Exact Sciences Corporation (EXAS) grew revenue by 17.7% over the past year. This is strong growth.
Exact Sciences Corporation (EXAS) reported a net loss of $207.9M for fiscal year 2025.
Dividend & Returns
Exact Sciences Corporation (EXAS) has a return on equity (ROE) of -8.7%. Negative ROE indicates the company is unprofitable.
Exact Sciences Corporation (EXAS) generated $356.8M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More EXAS
Exact Sciences Corporation (EXAS) financial analysis — history, returns, DCA and operating performance tools
Full EXAS Stock Analysis
Analyst verdict, bull/bear case, risk factors and peer comparison
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates